Pfizer
Pfizer is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
EaRly impAct theraPy with ceftazidime-avibactam via rapID diagnostics versus standard of care antibiotics and diagnostics in patients with bloodstream infection, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales (“RAPID”)
Sponsor National University Of Singapore
- Start (EU)
- Not reported
- Latest update
- Estimated end
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients previously exposed to three-drug classes
Sponsor Pethema Fundacion
- Start (EU)
- Latest update
- Estimated end
- Not reported
C0371002 - Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-R338L) in adult male participants with moderately severe to severe hemophilia B (FIX:C≤2%) (BeneGene-2)
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Sponsor ABCSG GmbH
- Start (EU)
- Latest update
- Estimated end
C4391002 - A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
The rimegePant in RElation to obeSiTy in mIGrainE study
Sponsor Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Pfizer?
The 2026-10-09 snapshot links Pfizer to 7 distinct CTIS trials. Recorded services include Laboratory services, Safety reporting & pharmacovigilance, Project management, During Study Storage, among 15 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Pfizer?
The most frequently recorded therapeutic areas are Haematological Malignancies, Infectious Disease, Respiratory. Recorded phases include Phase 2, Phase 3, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Pfizer conducted?
The linked trials record locations in 19 countries, including Spain, Italy, Germany, Netherlands, Sweden. These are trial locations, not confirmed office locations or countries where Pfizer delivered services.
What can this page tell me about Pfizer's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 3 recorded name variants under Pfizer. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Pfizer B.V.
- Pfizer Inc.
- Pfizer S.L.